| Literature DB >> 31388400 |
Penelope Hey1, Timothy P Hanrahan1, Marie Sinclair1, Adam G Testro1, Peter W Angus1, Adam Peterson1, Stephen Warrillow2, Rinaldo Bellomo2, Marcos V Perini1, Graham Starkey1, Robert M Jones1, Michael Fink3, Tess McClure1, Paul Gow1.
Abstract
BACKGROUND: Acute liver failure (ALF) is a life-threatening syndrome with varying aetiologies requiring complex care and multidisciplinary management. Its changing incidence, aetiology and outcomes over the last 16 years in the Australian context remain uncertain. AIM: To describe the changing incidence, aetiology and outcomes of ALF in South Eastern Australia.Entities:
Keywords: Acute; Australia; Liver failure; Liver transplant; Paracetamol; Victoria
Year: 2019 PMID: 31388400 PMCID: PMC6669190 DOI: 10.4254/wjh.v11.i7.586
Source DB: PubMed Journal: World J Hepatol
Drugs and toxins implicated in cases of acute liver failure managed at the Victorian Liver Transplant Unit from 2002-2017
| Paracetamol | 84 | 11 | 3 |
| Antibiotics | 4 | 2 | 2 |
| Amoxicillin/clavulanate (2), clarithromycin, isoniazid | |||
| Infliximab | 2 | 2 | 2 |
| Illicit drugs | 4 | 1 | 1 |
| LSD, injected buprenorphine, amphetamines, MDMA | |||
| NSAIDs | 1 | 1 | 1 |
| Amanita phalloides | 1 | 1 | 1 |
| Herbal medicines | |||
| Black cohosh herb, kava kava | 2 | 2 | 2 |
| Other | |||
| Moxonidine, fenofibrate, chlorambucil | 3 | 1 | 1 |
ALF: Acute liver failure; ELT: Emergency liver transplantation; NSAIDs: Non-steroid anti-inflammatory drugs; LSD: Lysergic acid diethylamide; MDMA: Methylenedioxymethamphetamine; NSAIDs: Non-steroidal anti-inflammatory drugs
Figure 1Flowchart of outcomes of patients meeting criteria for acute liver failure.
Demographics and aetiology of acute liver failure managed at the Victorian Liver Transplant Unit in a historical cohort† compared to current series
| Referral rate | 1.2 [0.6;1.6] | 1.6 [1.3;1.7] | 0.020 | ||
| Age, yr, median [IQR] | 36 [27.0;48.0] | 40 [30.0;52.0] | 0.168 | ||
| Gender | |||||
| Male | 16 | 20.0 | 37 | 21.9 | |
| Female | 64 | 80.0 | 132 | 78.1 | 0.733 |
| Aetiology | |||||
| Paracetamol | 29 | 36.3 | 84 | 49.7 | 0.046 |
| Viral hepatitis | 11 | 13.8 | 26 | 15.3 | 0.734 |
| Hepatitis B | 8 | 10.0 | 20 | 11.8 | 0.669 |
| Hepatitis A | 3 | 3.8 | 4 | 2.4 | 0.538 |
| Varicella zoster | 0 | 0.0 | 1 | 0.1 | 0.491 |
| Herpes simplex | 0 | 0.0 | 1 | 0.1 | 0.491 |
| Non-paracetamol drug/toxin | 5 | 6.3 | 17 | 10.1 | 0.323 |
| Indeterminate | 27 | 33.8 | 21 | 12.4 | <0.001 |
| Autoimmune hepatitis | 0 | 0.0 | 9 | 5.3 | 0.036 |
| Other | 8 | 10.0 | 12 | 7.1 | 0.432 |
| Waitlisted for transplantation | 35 | 43.8 | 59 | 33.5 | 0.179 |
| Waitlist mortality | 9 | 25.7 | 8 | 13.6 | 0.139 |
| Liver transplantation | 26 | 32.5 | 42 | 24.9 | 0.206 |
| Transplant-free survival | 30 | 37.5 | 88 | 52.1 | 0.032 |
| Overall hospital survival | 50 | 62.5 | 122 | 72.2 | 0.122 |
Gow et al[12], 2001;
Referral rate per million population per year. IQR: Interquartile range.
Figure 2Rate of paracetamol induced acute liver failure per capita.
Outcomes of acute liver failure managed at the Victorian Liver Transplant Unit in a historical cohort† compared to the current series
| Paracetamol | 20 | 69.0 | 62 | 73.8 | 0.614 | 21 | 72.4 | 65 | 77.4 | 0.589 |
| Non-paracetamol | 10 | 19.6 | 26 | 30.6 | 0.160 | 29 | 56.9 | 57 | 67.1 | 0.230 |
| Viral hepatitis | 2 | 18.2 | 10 | 38.4 | 0.228 | 5 | 45.5 | 18 | 69.2 | 0.173 |
| HBV | 2 | 25.0 | 7 | 35.0 | 0.609 | 4 | 50.0 | 14 | 70.0 | 0.318 |
| HAV | 0 | 0.0 | 3 | 75.0 | 0.047 | 1 | 0.33 | 3 | 75.0 | 0.270 |
| Drug/toxin induced | 3 | 60.0 | 5 | 29.4 | 0.211 | 4 | 80.0 | 12 | 70.6 | 0.678 |
| Autoimmune hepatitis | 0 | 0.0 | 3 | 33.3 | - | 0 | 0.0 | 6 | 66.7 | - |
| Indeterminate hepatitis | 5 | 18.5 | 2 | 9.5 | 0.381 | 15 | 55.5 | 14 | 66.7 | 0.435 |
| Other | 0 | 0.0 | 6 | 50.0 | 0.017 | 5 | 62.5 | 7 | 58.3 | 0.852 |
Gow et al[12], 2001. TFS: Transplant-free survival; OS: Overall hospital survival; HBV: Hepatitis B virus; HAV: Hepatitis A virus.